IgGenix Inc.
South San Francisco, US · 6 known investors
IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases. The company uses its proprietary SEQ SIFTER™ platform to develop first-in-class therapeutic antibodies targeting allergic cascades.
Founders & leadership
KN
Kari NadeauScientific Co-Founder
Investors · 6
In the news
- IgGenix Raises $40 Million To Address Allergic Diseasespulse2.com · 2023
- IgGenix Holds First Close of $40M Series B Financing - FinSMEsfinsmes.com · 2023
- IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy - BioSpacebiospace.com · 2023
- IgGenix Raises $25M in Series A1 Funding - FinSMEsfinsmes.com · 2021
- IgGenix, Inc. - BIO Investment & Growth Summit 2026bigs.bio.org